- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03880006
Universal Coverage of Antiretroviral Treatment in Senegal
Leveraging Adaptive Implementation Strategies to Achieve Universal Coverage of Antiretroviral Treatment in Senegal
Study Overview
Detailed Description
The overarching goal of this study is to assess the feasibility, fidelity, and cost-effectiveness of a universal coverage of Antiretroviral Treatment (ART) intervention among individuals living with HIV who are not virally suppressed in Dakar and Ziguinchor, Senegal. Specific aims and hypotheses are as follows:
Specific Aim 1: Compare the effectiveness and durability of (a) the existing Standard of Care (SOC) in Senegal versus (b) individual Case Management (CM) programs to achieve sustained viral suppression (SVS) among people living with HIV in Senegal.
Hypothesis 1: The null hypothesis is that standard of care and case management will be equally effective at achieving sustained viral suppression. The alternate hypothesis is that case management will be 30% more effective at sustained viral suppression at 12 months compared to standard of care.
Specific Aim 2: Determine the cost-effectiveness of the universal treatment approach using the CM intervention.
Hypothesis 1: A Case Management approach will be more cost-effective at achieving sustained viral suppression among people living with HIV (PLHIV) versus the existing standard of care in Senegal.
This study is a randomized controlled trial (RCT) that uses an effectiveness-implementation hybrid design to test the effectiveness and durability of CM interventions in achieving SVS among PLHIV who are not virally suppressed. CM vs. SOC approaches will be assessed using an individual-level RCT of case management to improve viral suppression of those living with HIV at 12 months compared to the Senegal SOC. While viral suppression will be a primary outcome of this intervention, significant attention will be given to the collection of service and implementation outcomes to assess both the SOC and CM.
Study sites will include two government HIV treatment facilities in Ziguinchor, and two in Dakar. Participant enrollment into the study will take place at the study sites, and study arms (SOC or CM) will be assigned through individual randomization at the clinic level. Notably, the HIV treatment facilities in this study are existing government facilities given the partnership between this study and the Ministry of Health (MOH) of Senegal.
Eligible participants recruited through the study site health facilities will go through the consent process in private rooms within the project office and complete a structured 1-hour interviewer-administered questionnaire, which will serve as the baseline assessment. Participants will be enrolled into the study, by trained study staff at a study site.
Baseline assessment of study participants will include a socio-behavioral questionnaire and biological testing. The baseline questionnaire will assess demographic characteristics, socioeconomic status, mobility and migration history, behavioral characteristics, health and HIV treatment history, and HIV acquisition risks.
Follow up will involve visits at 3, 6, 9, and 12 months after the first visit. Questionnaires will be administered at each visit. Questionnaires assessing behavioral characteristics, mental health, social support, and ART treatment adherence will be administered at 6 months, and 12 months.
Abbreviated questionnaires will be re-administered at 3 and 9 months though no biological assessments will be completed at these time points. The questionnaires leverage existing instruments that have detailed assessments engagement in ART services as well as enacted, perceived, and intersectional stigma. In addition, the investigators will use implementation indicators that explore measures of acceptability, fidelity, appropriateness, and routinization of the CM intervention.
Biological samples using either aliquots of serum or dried blood spots (DBS) will be taken at baseline, 6 months, and 12 months to support syphilis testing, HIV viral load, and other sexually transmitted infections (STIs). Biological testing taken at baseline and will include testing currently being implemented through the SOC, and testing conducted at the additional visits will be supported by the study. All participants will also have the opportunity to receive referrals for additional medical care as needed at the clinics in which the study sites are housed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dakar, Senegal
- Institut d'hygiene sociale / polyclinique
-
Pikine, Senegal
- Centre de sante Dominique
-
Ziguinchor, Senegal
- Hopital regional de Ziguinchor
-
Ziguinchor, Senegal
- Hopital Silence de Ziguinchor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Is mentally sound and capable of providing consent to participate
- Agrees to complete HIV and syphilis testing
- Speaks either French, Wolof or both
- Has provided informed consent to participate in the study
- Resident of Senegal for the past 3 months
- Intention to live in Dakar or Ziguinchor for the next 12 months
- Agrees to complete all required biological testing described in the consent form and receive results
Exclusion Criteria:
- Under 18 years of age
- Demonstrates mental incapacity, under the influence of substances, or any other illness preventing comprehension of the study procedures and informed consent
- Does not agree to complete all required biological testing described in the consent form or receive results
- Has not provided informed consent to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of care
Participants assigned to the Senegalese standard of care treatment for people living with HIV.
|
|
Experimental: Case management
Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
|
Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV.
Individuals are assigned to a specific case manager who will provide support throughout the study.
The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral suppression among study participants measured through biological samples using either aliquots of serum or dried blood spots (DBS).
Time Frame: Viral suppression at 12 months of follow up
|
Biological samples using either aliquots of serum or dried blood spots will be taken at baseline, 6 months, and 12 months to support HIV viral load testing. Biological testing taken at baseline and will include testing currently being implemented through the SOC, and testing conducted at the additional visits will be supported by the study. All participants will also have the opportunity to receive referrals for additional medical care as needed at the clinics in which the study sites are housed. Sustained viral suppression is defines as quantitative viral load assessment with <1000 copies/ml at 12 months after initial randomization |
Viral suppression at 12 months of follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Loss-to-follow-up of study participation among study participants
Time Frame: Loss to follow up at 12 months
|
Numbers and proportions of participants remaining engaged in the study will be measured through study visits every 3 months.
Loss to follow up among participants in the existing Standard of Care study arm will be compared to the individual Case Management (CM) study arm to measure a difference in loss to follow up between the two study arms.
|
Loss to follow up at 12 months
|
Acceptability of CM intervention among study participants through self-reported measure.
Time Frame: 12 months
|
Acceptability of the CM intervention will be measured through self-reported measures collected through the social behavioral questionnaire.
Acceptability measure is leveraged from the Society of Implementation Research Collaboration instrument review.
|
12 months
|
Cost-effectiveness of the universal treatment approach using the CM intervention
Time Frame: 12 months
|
To determine the cost-effectiveness of the universal treatment approach using the CM intervention, we will perform a comprehensive costing of our study intervention, from the perspectives of both the healthcare system and the participants.
Our costing methodology will follow World Health Organization (WHO) recommendations for cost-effectiveness analysis, with estimates of unit costs compared against WHO's CHOosing Interventions that are Cost-Effective (CHOICE) global estimates for countries in Senegal's region.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stefan Baral, MD MPH, Johns Hopkins Bloomberg School of Public Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- IRB00007193
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Case management
-
National Taiwan University HospitalCompleted
-
Minneapolis Veterans Affairs Medical CenterCompletedDiabetes MellitusUnited States
-
New York State Psychiatric InstituteEmory UniversityCompletedDepressive Disorder | Bipolar Disorder | Mental Disorders, Severe | Schizophrenia and Related Disorders
-
Johns Hopkins UniversityJohns Hopkins Community PhysiciansWithdrawnSubstance-related DisorderUnited States
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Kaiser PermanenteNot yet recruiting
-
Dalin Tzu Chi General HospitalCompletedArthritis, Rheumatoid | Case Management | Managed Care ProgramsTaiwan
-
Yong Seog OhUnknown
-
National Clinical Research Coordination Center,...CompletedMajor Depressive Disorders | Senile; DepressionKorea, Republic of